Skip Nav Destination
Issues
November 2020
-
Cover Image
Cover Image
Inhibitor binding to ACE (top) and ACE2 (bottom) highlight important differences between the active sites which control substrate specificity and type of peptidase activity. In this issue of Clinical Science (volume 134, issue 21), Lubbe et al. provide insight into the structural biology of ACE and ACE2, and highlight how it has improved our understanding of their functions.
ISSN 0143-5221
EISSN 1470-8736
In this Issue
Review Articles
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery
Clin Sci (Lond) (2020) 134 (21): 2791–2805.
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV
Clin Sci (Lond) (2020) 134 (21): 2851–2871.
Commentaries
Extracellular RNA in kidney disease: moving slowly but surely from bench to bedside
Clin Sci (Lond) (2020) 134 (21): 2893–2895.
Research Articles
The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis
Sarah W.Y. Lok; Wai Han Yiu; Hongyu Li; Rui Xue; Yixin Zou; Bin Li; Kam Wa Chan; Loretta Y.Y. Chan; Joseph C.K. Leung; Kar Neng Lai; Sydney C.W. Tang
Clin Sci (Lond) (2020) 134 (21): 2873–2891.
